2024-03-28T19:26:29Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:00025141
2023-01-16T04:15:54Z
499:500:501
Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies
Nishiwaki, Satoshi
75038
Okuno, Shingo
75039
Suzuki, Kotaro
75040
Kurahashi, Shingo
75041
Sugiura, Isamu
75042
Hematological malignancies
Order of treatment
Solid tumors
Synchronous multiple primary malignant tumors
Treatment discontinuation
The existence of synchronous multiple primary malignant tumors was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment to both hematological malignancies and solid tumors appropriately. Background: Hematological malignancies are occasionally observed with synchronous multiple primary malignant tumors (sMPMTs) at diagnosis. We aimed to clarify the impact of sMPMTs on newly diagnosed hematological malignancies and determine the optimal treatment strategies. Patients and Methods: We analyzed the outcomes of 649 patients with hematological malignancies, including 19 patients with sMPMTs (2.9%), and compared the outcomes between patients with and without sMPMTs. Results: The overall survival (OS) and disease-free survival (DFS) rates for patients with sMPMTs were 77% and 70%, respectively, at 2 years; these rates were not statistically different from those for patients without sMPMTs (P = .17 and P = .64, respectively). Multivariate analysis showed that the presence of sMPMTs was not a significant prognostic factor for OS, DFS, or relapse (hazard ratio [HR] 1.48, 95% confidence interval [CI] 0.65-3.38, P = .35; HR 0.97, 95% CI 0.46-2.10, P = .97; and HR 0.79, 95% CI 0.29-2.14, P= .65). In patients with sMPMTs, the order of treatment was not a significant prognostic factor. However, discontinuation of treatment was a marginally favorable factor and might reflect a selection bias. Conclusion: The presence of sMPMTs was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment for both hematological malignancies and solid tumors at the physician’s discretion.
journal article
Elsevier
2017-12
application/pdf
Clinical Lymphoma Myeloma and Leukemia
12
17
e75
e85
http://doi.org/10.1016/j.clml.2017.09.006
http://hdl.handle.net/2237/27362
2152-2650
https://nagoya.repo.nii.ac.jp/record/25141/files/CLML_2017_435_Original_accepted_V1.pdf
eng
https://doi.org/10.1016/j.clml.2017.09.006
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/